Cargando…
Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy
BACKGROUND: Proton pump inhibitors (PPIs) are known to reduce the risk of upper gastrointestinal bleeding in patients on oral anticoagulants, and patients are increasingly on oral anticoagulants and PPI co-therapy. However, evidence is lacking on the safety and effectiveness of oral anticoagulants w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211274/ https://www.ncbi.nlm.nih.gov/pubmed/34138972 http://dx.doi.org/10.1371/journal.pone.0253310 |
_version_ | 1783709449610854400 |
---|---|
author | Lee, Hyun-Jung Kim, Hyung-Kwan Kim, Bong-Sung Han, Kyung-Do Park, Jun-Bean Lee, Heesun Lee, Seung-Pyo Kim, Yong-Jin |
author_facet | Lee, Hyun-Jung Kim, Hyung-Kwan Kim, Bong-Sung Han, Kyung-Do Park, Jun-Bean Lee, Heesun Lee, Seung-Pyo Kim, Yong-Jin |
author_sort | Lee, Hyun-Jung |
collection | PubMed |
description | BACKGROUND: Proton pump inhibitors (PPIs) are known to reduce the risk of upper gastrointestinal bleeding in patients on oral anticoagulants, and patients are increasingly on oral anticoagulants and PPI co-therapy. However, evidence is lacking on the safety and effectiveness of oral anticoagulants when co-administered with PPIs. METHODS: Among patients initiating oral anticoagulants (warfarin and non-vitamin K antagonist oral anticoagulants [NOACs], i.e. rivaroxaban, dabigatran, apixaban, and edoxaban) during 2013–2017, those concomitantly prescribed PPIs were identified (n = 19,851). The primary endpoint was hospitalization for major upper gastrointestinal bleeding, and secondary endpoints were death and ischemic stroke. RESULTS: During a mean 1.4 years of follow-up, the primary endpoint occurred in 512 (2.58%) patients. Overall, NOACs were associated with lower upper gastrointestinal bleeding risk after adjustment for age, sex, comorbidities and concomitant medications (adjusted hazard ratio 0.78, 95% confidence interval 0.65–0.94), compared to warfarin. There was no significant difference in upper gastrointestinal bleeding risk among the individual NOACs. This trend of reduced risk for upper gastrointestinal bleeding in NOACs compared to warfarin was consistent for both regular and reduced doses, throughout bleeding risk groups, and other subgroup analyses. NOACs were also associated with lower risk of death compared to warfarin. The risk for ischemic stroke was not significantly different among the oral anticoagulants in patients with atrial fibrillation. CONCLUSION: In patients on oral anticoagulant and PPI co-therapy, NOACs were associated with lower risk of upper gastrointestinal bleeding and mortality compared to warfarin, while there was no difference among the oral anticoagulants for stroke prevention. In patients on PPI therapy, NOACs may preferred over warfarin for decreasing risk of upper gastrointestinal bleeding and mortality. |
format | Online Article Text |
id | pubmed-8211274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-82112742021-06-29 Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy Lee, Hyun-Jung Kim, Hyung-Kwan Kim, Bong-Sung Han, Kyung-Do Park, Jun-Bean Lee, Heesun Lee, Seung-Pyo Kim, Yong-Jin PLoS One Research Article BACKGROUND: Proton pump inhibitors (PPIs) are known to reduce the risk of upper gastrointestinal bleeding in patients on oral anticoagulants, and patients are increasingly on oral anticoagulants and PPI co-therapy. However, evidence is lacking on the safety and effectiveness of oral anticoagulants when co-administered with PPIs. METHODS: Among patients initiating oral anticoagulants (warfarin and non-vitamin K antagonist oral anticoagulants [NOACs], i.e. rivaroxaban, dabigatran, apixaban, and edoxaban) during 2013–2017, those concomitantly prescribed PPIs were identified (n = 19,851). The primary endpoint was hospitalization for major upper gastrointestinal bleeding, and secondary endpoints were death and ischemic stroke. RESULTS: During a mean 1.4 years of follow-up, the primary endpoint occurred in 512 (2.58%) patients. Overall, NOACs were associated with lower upper gastrointestinal bleeding risk after adjustment for age, sex, comorbidities and concomitant medications (adjusted hazard ratio 0.78, 95% confidence interval 0.65–0.94), compared to warfarin. There was no significant difference in upper gastrointestinal bleeding risk among the individual NOACs. This trend of reduced risk for upper gastrointestinal bleeding in NOACs compared to warfarin was consistent for both regular and reduced doses, throughout bleeding risk groups, and other subgroup analyses. NOACs were also associated with lower risk of death compared to warfarin. The risk for ischemic stroke was not significantly different among the oral anticoagulants in patients with atrial fibrillation. CONCLUSION: In patients on oral anticoagulant and PPI co-therapy, NOACs were associated with lower risk of upper gastrointestinal bleeding and mortality compared to warfarin, while there was no difference among the oral anticoagulants for stroke prevention. In patients on PPI therapy, NOACs may preferred over warfarin for decreasing risk of upper gastrointestinal bleeding and mortality. Public Library of Science 2021-06-17 /pmc/articles/PMC8211274/ /pubmed/34138972 http://dx.doi.org/10.1371/journal.pone.0253310 Text en © 2021 Lee et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Lee, Hyun-Jung Kim, Hyung-Kwan Kim, Bong-Sung Han, Kyung-Do Park, Jun-Bean Lee, Heesun Lee, Seung-Pyo Kim, Yong-Jin Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy |
title | Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy |
title_full | Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy |
title_fullStr | Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy |
title_full_unstemmed | Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy |
title_short | Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy |
title_sort | risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211274/ https://www.ncbi.nlm.nih.gov/pubmed/34138972 http://dx.doi.org/10.1371/journal.pone.0253310 |
work_keys_str_mv | AT leehyunjung riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy AT kimhyungkwan riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy AT kimbongsung riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy AT hankyungdo riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy AT parkjunbean riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy AT leeheesun riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy AT leeseungpyo riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy AT kimyongjin riskofuppergastrointestinalbleedinginpatientsonoralanticoagulantandprotonpumpinhibitorcotherapy |